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Background. We investigated the incidence and outcome of progressive multifocal leukoencephalopathy (PML)
in human immunodeficiency virus (HIV)–infected individuals before and after the introduction of combination
antiretroviral therapy (cART) in 1996.
Methods. From 1988 through 2007, 226 cases of PML were reported to the Swiss HIV Cohort Study. By chart
review, we confirmed 186 cases and recorded all-cause and PML-attributable mortality. For the survival analysis,
25 patients with postmortem diagnosis and 2 without CD4+ T cell counts were excluded, leaving a total of 159
patients (89 before 1996 and 70 during 1996–2007).
Results. The incidence rate of PML decreased from 0.24 cases per 100 patient-years (PY; 95% confidence
interval [CI], 0.20–0.29 cases per 100 PY) before 1996 to 0.06 cases per 100 PY (95% CI, 0.04–0.10 cases per 100
PY) from 1996 onward. Patients who received a diagnosis before 1996 had a higher frequency of prior acquired
immunodeficiency syndrome–defining conditions ( ) but similar CD4+ T cell counts (60 vs. 71 cells/mL;Pp .007
), compared with patients who received a diagnosis during 1996 or thereafter. The median time to PML-Pp .25
attributable death was 71 days (interquartile range, 44–140 days), compared with 90 days (interquartile range, 54–
313 days) for all-cause mortality. The PML-attributable 1-year mortality rate decreased from 82.3 cases per 100
PY (95% CI, 58.8–115.1 cases per 100 PY) during the pre-cART era to 37.6 cases per 100 PY (95% CI, 23.4.–60.5
cases per 100 PY) during the cART era. In multivariate models, cART was the only factor associated with lower
PML-attributable mortality (hazard ratio, 0.18; 95% CI, 0.07–0.50; ), whereas all-cause mortality wasP ! .001
associated with baseline CD4+ T cell count (hazard ratio per increase of 100 cells/mL, 0.52; 95% CI, 0.32–0.85;
) and cART use (hazard ratio, 0.37; 95% CI, 0.19–0.75; ).Pp .010 Pp .006
Conclusions. cART reduced the incidence and PML-attributable 1-year mortality, regardless of baseline CD4+
T cell count, whereas overall mortality was dependant on cART use and baseline CD4+ T cell count.
Progressive multifocal leukoencephalopathy (PML) is
a demyelinating disease of the central nervous system
(CNS) that is caused by lytic replication of JC virus in
the CNS [1–3]. PML is rare but frequently fatal as
observed in the context of profound cellular immu-
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nodeficiency. The underlying conditions are diverse and
include hematological malignancy, chemotherapy,
transplantation, lymphocyte depletion, and exposure to
immunomodulatory antibodies that are administered
for the treatment of autoimmune diseases [4–9]. How-
ever, PML has been most frequently diagnosed in the
context of human immunodeficiency virus (HIV) in-
fection and AIDS [10, 11]. The reported prevalence of
PML among HIV-infected patients in the era before the
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introduction of combination antiretroviral therapy (cART) var-
ied from 0.3% to 8%, with less than one-tenth surviving for
11 year [2, 10, 11]. Specific antiviral treatment targeting JC
virus is lacking [12–16], and improvement of JC virus–specific
immunity after suppression of HIV replication is the mainstay
of therapy. Data from early after the introduction of cART
described less dramatic improvements for PML than for other
opportunistic diseases [17–19]. More recent studies report a
patient survival rate of up to 63%, but persisting neurologic
deficits occur in more than one-half of the survivors [13, 20–
23]. Factors that appear to be associated with survival include
PML as the primary manifestation of AIDS, high CD4+ T cell
count, low HIV RNA load, presence of JC virus–specific cy-
totoxic T lymphocytes, and low JC viral load in cerebral spinal
fluid (CSF) at diagnosis [23–26].
However, most data were obtained from retrospective case
series or were limited by small numbers and inconsistent case
definitions. The Swiss HIV Cohort Study (SHCS) provides the
unique opportunity to investigate PML from prospectively col-
lected data from over the past 20 years. The aim of this study
was to assess the incidence rate and risk factors for mortality
among HIV-infected individuals with PML.
PARTICIPANTS AND METHODS
Study participants. The SHCS is a prospective, clinic-based,
observational study of HIV-infected adults that was initiated
in 1988, with clinical and laboratory follow-up documented
every 6 months. Enrollment is independent of disease stage and
treatment [27]. The present study included all patients who
had received a diagnosis of PML from 1988 through August
2007. The diagnosis of PML has been encoded in the SHCS
database as either definitive (i.e., proven by histologic exami-
nation of a biopsy or postmortem tissue specimen) or pre-
sumptive (i.e., according to clinical, radiological, or laboratory
evidence). For the purpose of this study, diagnoses of PML in
the SHCS database were checked by individual chart review,
and confirmed diagnoses were classified using the following
previously established definitions [28]: (1) possible, by typical
neuroradiologic and clinical findings; (2) laboratory confirmed,
when JC virus DNA was detected in CSF; (3) definitive, when
confirmed by histologic examination of a brain biopsy or au-
topsy specimen. Data related to HIV infection, including age,
sex, transmission risk, prior AIDS-defining conditions, CD4+
and CD8+ T cell counts, HIV RNA load, treatment history, and
cause of death (using the International Statistical Classification
of Diseases, 10th Revision [29]) were obtained from the SHCS
database. Additional data, such as clinical course, neurora-
diological images, use of antiviral drugs, and supplementary
laboratory values, were extracted from the chart review. After
chart review, we excluded 10 patients who had received a di-
agnosis of another neurological disease and 30 additional pa-
tients who had received a diagnosis of presumed PML but
lacked neuroradiological images; thus, data on 186 of 226 pa-
tients were used to estimate the annual PML prevalence. For
the survival analysis, we excluded 25 additional patients for
whom PML was only diagnosed postmortem and another 2
patients whose CD4+ T cell counts at diagnosis were missing.
PML-attributable mortality was defined as death due to neu-
rological deterioration, including seizures and coma, that was
directly associated with PML. All-cause mortality was defined
as death due to any cause, including PML-attributable death.
To investigate the effect of cART on the incidence and outcome
of PML, 2 successive eras were defined according to the intro-
duction of cART in Switzerland in 1996: the pre-cART era
(1988–1995) and the cART era (1996–2007). cART was defined
as at least 2 nucleoside reverse-transcriptase inhibitors plus ei-
ther a protease inhibitor or a nonnucleoside reverse-transcrip-
tase inhibitor. Monodrug and dual-drug ART were defined as
1 nucleoside reverse-transcriptase inhibitor or a combination
of 2 nucleoside reverse-transcriptase inhibitors, respectively.
Statistics. Basic demographic characteristics, laboratory
values, and use of ART were compared using the x2 test for
categorical variables and the Mann-Whitney U test for contin-
uous variables. Incidence rates of PML were calculated using
the number of enrolled patients in the SHCS and the duration
of follow-up according to the 2 defined periods of 1988–1995
and 1996–2007. Survival patterns were displayed using Kaplan-
Meier plots of cumulative survival probabilities. Cox hazard
proportional models were used to estimate the hazard ratios
(HRs) of PML-attributable death during the first year after
diagnosis of PML. All patients were censored at 1 year after
diagnosis of PML if no death had occurred. Analyses were
conducted using Stata software, version 9.2 (Stata), for
Windows.
RESULTS
Patient characteristics. From 1988 through August 2007, 186
patients received a diagnosis of PML in the SHCS. Figure 1
shows that the annual PML prevalence was highest during the
pre-cART era (mean prevalence during 1993–1995, 0.9%).
From 1996 onward, the annual mean prevalence decreased to
0.1%. For the survival analysis, we included 159 of 186 patients.
Table 1 summarizes the demographic characteristics of the 159
patients. The median age was 37 years (interquartile range
[IQR]: 33–42 years); 74.2% of the patients were male. Of the
159 analyzed patients, only 3 (1.9%) were of non-white eth-
nicity. Almost one-half of the patients had prior AIDS-defining
conditions. It was not unexpected that Candida esophagitis and
Pneumocystits pneumonia were the most frequently diagnosed
diseases in patients with PML who had prior AIDS-defining
disease. Only 5 patients had received a diagnosis of cytomeg-
alovirus retinitis, and 6 had received a diagnosis of Kaposi
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Table 1. Characteristics of 159 human immunodeficiency virus (HIV)–infected individuals with progressive mul-
tifocal leukoencephalopathy (PML), according to the calendar period of PML diagnosis.
Variable
Patients
P
All
(n p 159)
PML diagnosis
before 1996
(n p 89)
PML diagnosis during
1996 or thereafter
(n p 70)
Age, median years (IQR) 37 (33–42) 35 (32–41) 39 (35–43) .002
Male sex 118 (74.2) 65 (73.0) 53 (75.1) .701
Transmission risk
MSM 49 (30.8) 23 (25.8) 26 (37.1) .414
Heterosexual contact 27 (17.0) 15 (16.9) 12 (17.1)
IDU 79 (49.7) 49 (55.1) 30 (42.9)
Other 4 (2.5) 2 (2.2) 2 (2.9)
ART at time of PML diagnosis
None 45 (28.3) 30 (33.7) 15 (21.4) !.001
Monodrug or dual-drug ART 65 (40.9) 59 (66.3) 6 (8.6)
cART 49 (30.8) 0 (0) 49 (70.0)
Prior AIDS-defining condition 76 (47.8) 51 (57.3) 25 (35.7) .007
CD4+ T cell count, median cells/mL (IQR) 60 (23–140) 60 (20–140) 71 (31–132) .250
CD8+ T cell count, median cells/mL (IQR) 488 (271–805) 480 (236–776) 514 (361–805) .336
HIV RNA level, median log10 copies/mL
a (IQR) 4.9 (3.5–5.4) 4.9 (4.1–5.5) 4.9 (3.3–5.4) .755
NOTE. Data are no. (%) of patients unless otherwise indicated. Boldface type indicates statistical significance. ART, antiretroviral
therapy; cART, combination ART; IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men.
a Data were available for 68 patients.
sarcoma, which could not be further analyzed. The median
CD4+ T cell count at PML diagnosis was 60 cells/mL (IQR, 23–
140 cells/mL). Plasma HIV RNA levels were available for 68
patients; the median was 4.9 log10 copies/mL (IQR, 3.5–5.4 log10
copies/mL). Most patients (71.7%) were receiving ART when
PML was diagnosed, but only 30.8% were receiving cART. In-
jection drug use was an HIV transmission risk factor for one-
half of the patients, and one-third of the patients were men
who have sex with men. PML was diagnosed on the basis of
typical clinical and neuroradiological signs in 95 patients (60%),
was laboratory confirmed in 38 patients (24%), and was de-
finitive in 26 patients (16%). Magnetic resonance imaging was
performed for 133 patients (84%). Polymerase chain reaction
(PCR) of CSF specimens for JC virus DNA was performed for
81 patients (51%), and JC virus DNA was detectable in ap-
proximately one-half of these patients. The 25 patients with a
postmortem diagnosis were similar with regard to baseline age,
sex, transmission risk, and CD4+ T cell count at baseline; how-
ever, these patients had more frequently received a diagnosis
of another AIDS-defining condition before 1996 than from
1996 onward.
Outcome of PML in Switzerland. After diagnosis of PML,
25 (15.7%) patients started cART, 8 (5.0%) received cidofovir,
and 2 (1.2%) received cytarabine. Overall, 97 patients died
within 1 year after diagnosis; the median survival time was 90
days (IQR, 53–312 days), which corresponds to a 1-year mor-
tality rate of 119.0 deaths per 100 person-years (PY; 95% CI,
98.1–144.4 deaths per 100 PY). Of those 97 patients, 51 died
of PML, corresponding to a PML-attributable 1-year mortality
rate of 58.9 deaths per 100 PY (95% CI, 44.8–77.6 deaths per
100 PY). The median time from diagnosis to PML-attributable
death was 71 days (IQR, 44–140 days). Of 62 patients with
PML who lived for 11 year after diagnosis, long-term follow-
up data were available for 47. Of these 47 patients, 39 (83%)
had persisting neurological deficits and only 8 (17%) showed
clinical improvement.
PML during the pre-cART and cART eras. Of 159 patients
with PML, 89 (56.0%) received a diagnosis during the period
1988–1995 and 70 (44.0%) received a diagnosis during the
period 1996–2007. The incidence rate of PML decreased by 4-
fold from 0.24 cases per 100 PY (95% CI, 0.20–0.29 cases per
100 PY) during the pre-cART era to 0.06 cases per 100 PY
(95% CI, 0.04–0.10 cases per 100 PY) during the cART era.
Sex, transmission risk, and importantly, CD4+ T cell counts
were similar in the 2 groups (table 1). Individuals in the pre-
cART era had significantly more prior AIDS-defining condi-
tions ( ), were more likely to have been receivingPp .007
monodrug or dual-drug ART ( ), and more frequentlyP ! .001
received a diagnosis of possible PML ( ), comparedPp .002
with patients in the cART era.
Risk factors for PML-attributable mortality. The PML-
attributable 1-year mortality rate decreased by approximately
one-half, from 82.3 deaths per 100 PY (95% CI, 58.8–115.1
deaths per 100 PY) during the pre-cART era to 37.6 deaths per
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Figure 1. Prevalence of progressive multifocal leukoencephalopathy (PML) per year among the participants of the Swiss HIV Cohort Study (SHCS)
who received annual follow-up.
Figure 2. Kaplan-Meier estimates of survival after diagnosis of progressive multifocal leukoencephalopathy (PML), according to the calendar year
of PML diagnosis.
100 PY (95% CI, 23.4–60.5 deaths per 100 PY) during the
cART era. The Kaplan-Meier estimates were significantly dif-
ferent between both time periods (figure 2).
In the univariate analysis, patients treated with cART (HR,
0.20; 95% CI, 0.09–0.48; ) and those who received aP ! .001
diagnosis from 1996 onward (HR, 0.50; 95% CI, 0.28–0.90;
) had a lower risk of PML-attributable death withinPp .020
the first year after PML diagnosis (table 2), compared with
patients who were not treated with cART and received a di-
agnosis before 1996. We did not observe any association be-
tween female sex and survival (HR, 1.51; 95% CI, 0.85–2.69;
) when all patients were included (table 2) or whenPp .159
only injection drug users were considered (HR, 1.06; 95% CI,
0.50–2.27; ). In the multivariate analysis, after adjust-Pp .881
ment for age, CD4+ T cell count, ART, and calendar period,
treatment with cART at PML diagnosis was the only prognostic
factor for survival (HR, 0.18; 95% CI, 0.07–0.50; ) (tableP ! .001
3). cART use also remained the only prognostic factor when
HIV RNA load was included in a model (HR, 0.25; 95% CI,
0.08–0.79; ) with 68 patients whose HIV RNA load dataPp .01
were available. Kaplan-Meier estimates, stratified by treatment
modality at PML diagnosis, are shown in figure 3.
Risk factors for all-cause mortality. In the univariate anal-
ysis, a CD4+ T cell count 1100 cells/mL (HR, 0.66; 95% CI,
HIV/AIDS • CID 2009:48 (15 May) • 1463
Table 2. Risk factors and univariate hazard ratios (HRs) of pro-
gressive multifocal leukoencephalopathy (PML)–attributable
death among 159 human immunodeficiency virus (HIV)–infected
individuals.
Variable HR (95% CI) P
Age, per 10-year increase 1.19 (0.81–1.73) .373
Female vs. male sex 1.51 (0.85–2.69) .159
Transmission risk
MSM 1a
Heterosexual contact 0.71 (0.29–1.72) .442
IDU 1.12 (0.61–2.08) .710
Prior AIDS-defining condition 1.37 (0.79–2.38) .258
CD4+ T cell count, cells/mL
!50 1a
50–100 1.27 (0.63–2.53) .501
1100 0.75 (0.40–1.43) .389
HIV RNA level, log10 copies/mL
b
!4.0 1a
4.0–5.0 3.12 (0.61–16.1) .173
15.0 4.09 (0.88–19.0) .072
ART at time of PML diagnosis
None 1a
Mono or dual ART 0.68 (0.38–1.23) .206
cART 0.20 (0.09–0.48) !.001
PML diagnosis during 1996 or thereafter 0.50 (0.28–0.90) .020
NOTE. Boldface type indicates statistical significance. ART, antiretroviral
therapy; cART, combination ART; IDU, injection drug use; MSM, men who
have sex with men; 95% CI, 95% confidence interval.
a Reference category.
b Data were available for 68 patients.
Table 3. Risk factors and multivariate hazard ratios (HRs) of
progressive multifocal leukoencephalopathy (PML)–attributa-
ble death among 159 human immunodeficiency virus–infected
individuals.
Variable HRb (95% CI) P
Age, per 10-year increase 1.36 (0.94–1.98) .103
CD4+ T cell count, cells/mL
!50 1a
50–100 1.08 (0.53–2.19) .832
1100 0.69 (0.36–1.33) .267
ART at time of PML diagnosis
None 1a
Monodrug or dual-drug ART 0.70 (0.37–1.31) .265
cART 0.18 (0.07–0.50) !.001
PML diagnosis during 1996 or thereafter 1.03 (0.49–2.17) .941
NOTE. Boldface type indicates statistical significance. ART, antiretroviral
therapy, cART, combination ART; 95% CI, 95% confidence interval.
a Reference category.
b Adjusted for all variables listed in the table.
0.45–0.98; ), use of cART (HR, 0.33; 95% CI, 0.19–Pp .044
0.58; ), and PML diagnosis from 1996 onward (HR,P ! .001
0.51; 95% CI, 0.34–0.76; ) were associated with lowerPp .01
all-cause mortality. In the multivariate analysis, after adjust-
ment for age, CD4+ T cell count, ART, and calendar period, a
CD4+ T cell count 1100 cells/mL (HR, 0.52; 95% CI, 0.32–0.85;
), and use of cART (HR, 0.37; 95% CI, 0.19–0.75;Pp .010
) were associated with a higher survival rate (table 4).Pp .006
DISCUSSION
PML is a devastating disease that confronts patients and phy-
sicians with progressive disability and high mortality. Although
the pathology and its viral etiology have been known for 140
years [30, 31], PML has been difficult to study, in part, because
of the erratic manifestation in patients characterized by severe
chronic conditions with profound cellular immunodeficiency.
This hallmark has also been emphasized in the recent PML
cases in patients with autoimmune diseases treated with new
potent immunosuppressive therapies [4–9]. Even for patients
with HIV infection or AIDS, in whom most cases occurred in
the past, few studies enrolled 150 patients with consistently
collected longitudinal data [13, 22, 23, 26].
Our comprehensive study of almost 200 PML cases diag-
nosed over 20 years of the SHCS enumerates the incidence rate
of PML as 0.24% during the pre-cART era of HIV infection
and AIDS. The introduction of cART in Switzerland in 1996
was associated with a 4-fold decrease in PML incidence to
0.06%. The decrease in PML incidence from 1996 onward sup-
ports the notion that preservation of overall immune functions
by cART is a key factor protecting against the manifestation of
PML. Indeed, we found that the median CD4+ T cell counts
were similarly low in both eras (60 cells/mL and 70 cells/mL
during the pre-cART and cART eras, respectively) at the time
of PML diagnosis. In addition to preventing decreases in CD4+
T cell count, however, cART-mediated suppression of HIV rep-
lication may exert a direct beneficial effect in the CNS by in-
terfering with HIV-tat mediated activation of JC virus repli-
cation [32, 33].
Our study also revealed that cART has significantly reduced
the PML-attributable 1-year mortality rate from 82.3 deaths
per 100 PY during the pre-cART era to 37.6 deaths per 100
PY during the cART era. This improvement of the 1-year sur-
vival rate in association with cART was independent of HIV
RNA load and the total CD4+ T cell count at diagnosis. How-
ever, a case-control study that compared HIV-infected patients
with PML and HIV-infected control subjects matched by CD4+
T cell count supports the view that the JC virus–specific T cell
responses, not the overall CD4+ T cell count, may be critical
for PML survival [34]; JC virus–specific cytotoxic CD8+ T cell
responses seem to be the most critical [24]. Conversely, our
study indicated that all-cause mortality among patients with
PML was associated with a lower CD4+ T cell count at baseline,
which reflects the higher risk of opportunistic disease burden
with increasing immunodeficiency. No corresponding data
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Figure 3. Kaplan-Meier curve of progressive multifocal leukoencephalopathy (PML)–attributable death, according to antiretroviral treatment (ART)
modality, among 159 patients who received a diagnosis of PML. cART, combination ART.
Table 4. Risk factors and multivariate hazard ratios (HRs) of all-
cause mortality among 159 human immunodeficiency virus–in-
fected individuals with progressive multifocal leukoencephalopa-
thy (PML).
Variable HRb (95% CI) P
Age, per 10-year increase 1.05 (0.80–1.39) .716
CD4+ T cell count, cells/mL
!25 1a
25–50 0.56 (0.29–1.07) .100
50–100 0.73 (0.42–1.26) .257
1100 0.52 (0.32–0.85) .010
ART at time of PML diagnosis
None 1a
Mono or dual ART 0.79 (0.49–1.27) .328
cART 0.37 (0.19–0.75) .006
PML diagnosis during 1996 or thereafter 0.87 (0.48–1.57) .644
NOTE. Boldface type indicates statistical significance. ART, antiretroviral
therapy; cART, combination ART; 95% CI, 95% confidence interval.
a Reference category.
b Adjusted for all variables listed in the table.
from other immunodeficient HIV-uninfected patients are avail-
able, but case series support the view that the prognosis of PML
may be significantly worse in conditions that do not allow
improvement of anti–JC virus immunity without adverse out-
comes for the underlying condition (e.g., neoplasia, transplan-
tation, or autoimmune disease) [6, 35, 36]. On the other hand,
brisk recovery of immunity may cause immune reconstitution
inflammatory syndrome (IRIS), a potentially fatal complication
after initiation of cART [37–39]. The frequency of IRIS may
be more pronounced among patients with low CD4+ cell counts
[38]. The rate of IRIS among patients with PML varied con-
siderably between different studies and was as high as 23%
[40]. In our study, only 4 patients (2.5%) with IRIS were re-
ported in the SHCS, most likely because of underdiagnosis. Of
interest, in a recent study, no difference in mortality among
patients with PML with or without IRIS was observed [40].
PML is typically diagnosed on the basis of examination of
focal neurological deficits in immunodeficient patients and rep-
resents a late complication of HIV infection or AIDS. Therefore,
during the cART era, patients with PML must have either re-
ceived a late diagnosis of HIV infection or must have had
deferred treatment because of personal choice, drug intoler-
ance, or comorbidities, including psychiatric disorders. In this
context, it is interesting to note that there was a higher pro-
portion of injection drug users among patients with PML in
both eras, compared with the entire SHCS population. How-
ever, we cannot exclude that injection drug use might also
represent a behavioral risk factor for JC virus transmission.
Limitations of our study are those inherent to observational
cohort studies in which patients are not randomized. Therefore,
diagnosis, examination, and interventions are dependent on the
treating physician and are subject to selection bias. The gold
standard of PML diagnosis is histologic examination of a brain
biopsy specimen, which is highly specific but also invasive and
costly, and results may be false negative as a result of necrosis
[41]. Detection of JC virus in CSF by PCR became available
in the 1990s and is now widely accepted for laboratory-con-
firmed diagnosis [28]. In HIV-infected patients with typical
radiological lesions, the specificity of JC virus PCR of CSF is
190%, but the sensitivity ranges from 70% to 90% [42, 43].
In the SHCS, JC virus DNA was not detectable in CSF speci-
mens from two-thirds of patients who received a histological
diagnosis. In addition, we cannot account for changes in these
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parameters, because the methodology of JC virus detection in
CSF changed from nested PCR to a real-time format during
the past 10 years. Therefore, neither the performance of the JC
virus PCR test used at the SHCS centers nor the potential role
of the test result as a marker for patient survival could be
assessed. A recent study reported that the sensitivity of JC virus
DNA detection decreased from 90% to ∼60% during the cART
era. Exposure to cART and a high CD4+ T cell count were
identified as predictors of diagnostic failure [44]. Therefore,
PML diagnosis is frequently based on compatible clinical and
radiological findings. Together, these emphasize the need for
cautious interpretation of negative CSF findings in patients with
otherwise typical PML.
To date, there are no successful antiviral therapies for PML
that effectively suppress JC virus replication. In HIV-infected
patients with PML, the additional use of cidofovir, a nucleotide
analogue with in vitro activity against JC virus, has shown
contradictory results in several studies [12–16]. A prospective
nonrandomized analysis and a recent large multicenter cohort
study report lack of additional efficacy with the addition of
cidofovir to cART [13, 16]. In our population, cytarabine and
cidofovir were rarely used, and the efficacy of these drugs could
not be investigated.
In conclusion, the results of this study, covering 20 years of
the SHCS database, demonstrate that the introduction of cART
has led to a decrease in the incidence of PML among HIV-
infected patients and has reduced PML-attributable 1-year mor-
tality, regardless of baseline CD4+ T cell count.
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